Intellia Therapeutics Inc (NTLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$9.05
Buy
$9.09
$0.12 (+1.33%)
Prices updated at 15 Dec 2025, 13:59 EST
| Prices minimum 15 mins delay
Prices in USD
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 16.66 |
| 2024 | 25.98 |
| 2023 | 52.48 |
| 2022 | 51.08 |
| 2021 | 298.37 |
| 2020 | 46.25 |
| 2019 | 16.84 |
| 2018 | 19.53 |
| 2017 | 26.72 |
| 2016 | 37.62 |
Price/Forward earnings (YTD)
-2.50
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -41.66 |
| 2023 | -34.11 |
| 2022 | -33.69 |
| 2021 | -27.19 |
| 2020 | -26.56 |
| 2019 | -29.21 |
| 2018 | -23.59 |
| 2017 | -20.01 |
| 2016 | -16.60 |
| 2015 | -26.71 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.37 |
| 2023 | 1.24 |
| 2022 | 1.23 |
| 2021 | 1.24 |
| 2020 | 1.28 |
| 2019 | 1.24 |
| 2018 | 1.25 |
| 2017 | 1.25 |
| 2016 | 1.42 |
| 2015 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
